A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral Administration of a 80 mg Febuxostat Extended-Release (XR) Capsule Formulation
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs Febuxostat (Primary) ; Aluminium hydroxide/magnesium hydroxide/simethicone
- Indications Gout; Hypertension; Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Takeda
- 21 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 31 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
- 31 Mar 2015 Planned primary completion date changed from 31 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.